BeOne Medicines Ltd. American Depositary Shares (ONC) Stock Price

ONCStock

$369.06+20.61%52W

Market Cap$41.99B

P/E184.78x

PEG Ratio0.78

Div yield—

Beta1.47

ONC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.93%

Price vs S&P 500 (4W)4.83%

PEG Ratio0.78

VGM Score62.62

P/E Ratio (Annual)184.78x

P/CF (Annual)19.68x

Book Value / Share (Quarterly)$3.60

P/TBV (Annual)9.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.68%

Cash Flow / Share (Quarterly)$1.56

Payout Ratio (TTM)8.18%

Price vs S&P 500 (YTD)-15.05%

Gross Margin (TTM)88.54%

Net Profit Margin (TTM)9.97%

EPS (TTM)$0.42

10-Day Avg Trading Volume3.00M

EPS Excl Extra (TTM)$0.42

Revenue Growth (5Y)78.32%

EPS (Annual)$0.15

Dividend / Share (Annual)$0.04

ROI (Annual)3.81%

Gross Margin (Annual)87.43%

Net Profit Margin (5Y Avg)-64.81%

Cash / Share (Quarterly)$3.62

P/E Basic Excl Extra (TTM)63.04x

Revenue Growth QoQ (YoY)23.28%

P/E Normalized (Annual)184.78x

ROA (Last FY)2.55%

Revenue Growth TTM (YoY)31.13%

EBITD / Share (TTM)$0.57

ROE (5Y Avg)-22.39%

Operating Margin (TTM)13.71%

Cash Flow / Share (Annual)$1.27

P/B Ratio7.62x

P/B Ratio (Quarterly)6.76x

Net Income / Employee (Annual)$18,453

EV / Revenue (TTM)6.02x

Net Interest Coverage (TTM)-132.16x

ROA (TTM)7.35%

EPS Growth QoQ (YoY)207.93%

EV / EBITDA (TTM)43.89x

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)3.47x

Quick Ratio (Quarterly)3.06x

3-Month Avg Trading Volume4.93M

52-Week Price Return20.61%

EV / Free Cash Flow (Annual)21.04x

P/E Incl Extra (TTM)63.04x

Revenue / Employee (TTM)$542,394

Tangible BV / Share (Quarterly)$3.48

P/S Ratio (Annual)7.06x

Asset Turnover (Annual)0.67x

52-Week High$47.70

Operating Margin (5Y Avg)-65.13%

EPS Excl Extra (Annual)$0.15

CapEx CAGR (5Y)7.69%

26-Week Price Return6.97%

Quick Ratio (Annual)3.06x

13-Week Price Return-4.43%

Total Debt / Equity (Annual)0.25x

Current Ratio (Quarterly)3.49x

Enterprise Value$38.58B

Revenue / Share Growth (5Y)74.43%

Asset Turnover (TTM)0.74x

Revenue / Employee (Annual)$483,001

Inventory Turnover (Annual)1.22x

Pretax Margin (Annual)6.79%

Cash / Share (Annual)$3.32

3-Month Return Std Dev48.87%

Gross Margin (5Y Avg)84.47%

Net Income / Employee (TTM)$54,103

EBITDA Interim CAGR (5Y)36.09%

ROE (Last FY)4.77%

Net Interest Coverage (Annual)-8.59x

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)17.55x

Receivables Turnover (TTM)6.83x

EV / Free Cash Flow (TTM)16.79x

Total Debt / Equity (Quarterly)0.22x

EPS Incl Extra (TTM)$0.42

Receivables Turnover (Annual)7.05x

ROI (TTM)10.67%

P/S Ratio (TTM)6.29x

Pretax Margin (5Y Avg)-62.15%

Revenue / Share (Annual)$3.83

Tangible BV / Share (Annual)$3.05

Forward P/E50.61x

Price vs S&P 500 (52W)22.40%

P/E Ratio (TTM)63.04x

Year-to-Date Return-4.70%

5-Day Price Return3.21%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)-14.78%

Net Profit Margin (Annual)3.82%

Month-to-Date Return-3.19%

EBITD / Share (Annual)$0.31

Operating Margin (Annual)6.80%

LT Debt / Equity (Annual)0.22x

P/CF (TTM)16.34x

ROI (5Y Avg)-18.89%

P/E Excl Extra (TTM)63.04x

LT Debt / Equity (Quarterly)0.17x

EPS Basic Excl Extra (TTM)$0.42

P/TBV (Quarterly)7.00x

Payout Ratio (Annual)24.02%

P/B Ratio (Annual)8.68x

Dividend / Share (TTM)$0.04

Inventory Turnover (TTM)1.15x

Pretax Margin (TTM)13.70%

Book Value / Share (Annual)$3.18

Price vs S&P 500 (13W)-7.11%

Dividend Yield (TTM)0.13%

Beta1.47x

P/FCF (Annual)21.99x

Revenue / Share (TTM)$4.17

ROE (TTM)13.33%

52-Week Low$30.71

vGradeD

gGradeB

mGradeB

vgmGradeB

ONC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.24	$0.31	+25.66%(+$0.06)
Q1 2026	May 6, 2026	$0.12	$0.29	+143.25%(+$0.17)
Q4 2025	Feb 26, 2026	$0.19	$0.09	-55.33%(-$0.11)
Q3 2025	Nov 6, 2025	$0.13	$0.16	+26.99%(+$0.03)
Q2 2025	Aug 6, 2025	$0.04	$0.13	+224.26%(+$0.09)

ONC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes targeted cancer treatments. The company's portfolio includes BRUKINSA (a Bruton's tyrosine kinase inhibitor), sonrotoclax (a BCL2 inhibitor), and other proprietary therapeutics. BeOne generates revenue primarily from the sale of its biopharmaceutical products across multiple oncology indications.

ONC Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.28

Revenue estimate$262.69M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ONC Insider Transactions

SellSep 1, 2026
BALL TITUS BENJAMIN
Officer
Shares: 132Value: $46,974
SellAug 25, 2026
WU XIAOBIN
President
Shares: 280Value: $106,400
SellAug 12, 2026
OYLER JOHN VICTOR
Chief Executive Officer
Shares: 240,810Value: $86.48M
SellAug 11, 2026
LEE CHAN HENRY
General Counsel
Shares: 2,666Value: $959,760
SellAug 3, 2026
ROSENBERG AARON
Chief Financial Officer
Shares: 1,157Value: $361,811

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

APDAir Products & Chemicals, Inc.Industrial Chemicals
ARGXargenx SE American Depositary SharesBiological Products
HLNHaleon plc American Depositary Shares (Each representing two Ordinary Shares)Cosmetics & Toiletries
IDXXIdexx Laboratories IncIn Vitro Diagnostics
RVMDRevolution Medicines, Inc. Common StockBiological Products
ELThe Estee Lauder Companies Inc. Class ACosmetics & Toiletries
KVUEKenvue Inc.Cosmetics & Toiletries
BIIBBiogen Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

Price Range (33 wk)

Low$260.27

High$376.86